In 2016, research showed that ZNF217 inhibited the m6A methylation of KLF4 and NANOG mRNA, which was catalyzed by METTL3 and resulted in elevated KLF4 and NANOG protein levels, which in turn promoted the progression of breast cancer [70]. Here, METTL3 is linked to breast carcinoma.